Evidence mapPaperPMID 41744227Full record

ArticleBriefings in bioinformatics2026

Artificial intelligence-powered prediction of diabetic complications: from clinical data to molecular omics.

Xueqin Xie, Changchun Wu, Ziru Huang, Yuwei Zhou, Jian Huang, Fuying Dao, Dan Yan, Kejun Deng, Hao Lyu, Caiyi Ma and 1 more

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Burden of Diabetic Kidney Disease at Global, Regional, and National Levels From 1990 to 2021].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xueqin XieDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, 2006 Xiyuan Avenue, West Hi-Tech Zone, Chengdu 610054, China.
Changchun WuDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, 2006 Xiyuan Avenue, West Hi-Tech Zone, Chengdu 610054, China.
Ziru HuangDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, 2006 Xiyuan Avenue, West Hi-Tech Zone, Chengdu 610054, China.
Yuwei ZhouDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, 2006 Xiyuan Avenue, West Hi-Tech Zone, Chengdu 610054, China.
Jian HuangDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, 2006 Xiyuan Avenue, West Hi-Tech Zone, Chengdu 610054, China.ORCID 0000-0003-3282-8892
Fuying DaoSchool of Biological Sciences, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798, Singapore.
Dan YanBeijing Friendship Hospital, Capital Medical University, 10 Xitoutiao Road, Youanmenwai Avenue, Fengtai District, Beijing 100069, China.
Kejun DengDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, 2006 Xiyuan Avenue, West Hi-Tech Zone, Chengdu 610054, China.ORCID 0000-0003-0411-549X
Hao LyuDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, 2006 Xiyuan Avenue, West Hi-Tech Zone, Chengdu 610054, China.ORCID 0000-0002-7580-0155
Caiyi MaSchool of Computer Science and Technology, Aba Teachers College, Shuimo Town, Wenchuan 623002, China.
Hao LinDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, 2006 Xiyuan Avenue, West Hi-Tech Zone, Chengdu 610054, China.ORCID 0000-0001-6265-2862

Funding

China Postdoctoral Science Foundation 2023TQ0047China Postdoctoral Science Foundation GZC20230380Fundamental Research Funds for the Central Universities ZYGX2024Z011National Natural Science Foundation of China 62402089National Natural Science Foundation of China 625B2035National Natural Science Foundation of China 82130112National Natural Science Foundation of China U24A20789Science and Technology Department of Sichuan Province 2025ZNSFSC1465
6 · The paper itself

Abstract

Diabetic complications are a major cause of disability and mortality among patients, and early identification of high-risk individuals is essential for precision prevention and management. In recent years, the rapid advancement of artificial intelligence (AI) has provided transformative tools for risk prediction and clinical decision support in diabetes care. In this narrative review, we systematically surveyed studies published between January 2015 and June 2025 in PubMed, Web of Science, and Scopus that applied AI-based predictive modeling for three major diabetic complications: diabetic retinopathy (DR), diabetic nephropathy (DN), and diabetic cardiovascular disease (CVD). A total of 58 studies were included, encompassing models based on clinical features, molecular omics, medical imaging, and multimodal data integration. Cross-scale and multimodal data fusion has emerged as a promising new paradigm, demonstrating improved predictive performance over single-modality approaches in three major diabetic complications. We also summarize the evolution from traditional machine learning to deep learning and, more recently, to large language models and agent-based systems, comparing their methodological characteristics, strengths, and suitable application scenarios. Finally, we proposed an actionable six-step framework and clinical translation pathway for AI in diabetic complications, outlining key steps from data curation and model development to validation, regulatory compliance, and real-world implementation. Together, these insights provide a roadmap toward developing robust, transparent, and clinically deployable AI systems capable of transforming the prevention and management of diabetic complications.

Indexed as

artificial intelligencediabetic complicationslarge language modelsmachine learningrisk prediction

Identifiers

PMID41744227
PMCPMC12936790

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.